Final safety results from ATHENA-MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer

被引：0

作者：

O'Malley, David M.

Monk, Bradley J.

Lim, Myong Cheol

Pradera, Jose Fuentes

Buscema, Joseph

Wilson, Michelle K.

De Vivo, Rocco

Herzog, Thomas J.

Zagouri, Flora

Oza, Amit M.

Mikheeva, Olga N.

Diaz, John Paul

Lisyanskaya, Alla Sergeevna

Morris, Robert

Bruchim, Ilan

Craib, Marcia

Connor, Christy

Shih, Danny

Fujiwara, Keiichi

Kristeleit, Rebecca

机构：

[1] Ohio State Univ, Div Gynecol Oncol, James Canc Ctr, Columbus, OH USA

[2] Creighton Univ, Univ Arizona, GOG Fdn, Coll Med,Sch Med, Phoenix, AZ USA

[3] Natl Canc Ctr Korea, Gynecol Oncol, Goyang Si, Gyeonggi Do, South Korea

[4] Hosp Univ Virgen Valme, Seville, Spain

[5] Arizona Oncol Associates, Tucson, AZ USA

[6] Auckland City Hosp, Dept Canc & Blood, Auckland, New Zealand

[7] Osped San Bortolo, Dept Med Oncol, Vicenza, Italy

[8] Univ Cincinnati, Cincinnati, OH USA

[9] Alexandra Hosp, Dept Clin Therapeut, Athens, Greece

[10] Princess Margaret Hosp Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada

[11] Ltd Liabil Co MedPomosch, St Petersburg, Russia

[12] Baptist Hlth South Florida, Miami Canc Inst, Miami, FL USA

[13] St Petersburg State Budget Healthcare Inst, City Clin Oncol Dispensary, St Petersburg, Russia

[14] Wayne State Univ, Karmanos Canc Inst, Div Gynecol Oncol, Dept Oncol,Sch Med, Detroit, MI USA

[15] Rappaport Fac Med, Hillel Yaffe Med Ctr, Hadera, Israel

[16] Pharma&, Stat Programming, New York, NY USA

[17] Pharma&, Clin Operat, New York, NY USA

[18] Saitama Med Univ Int Med Ctr, Dept Gynecol Oncol, Hidaka, Saitama, Japan

[19] Guys & St Thomas NHS Fdn Trust, Dept Oncol, London, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5554

引用

页数：1

共 50 条

[1] A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)
Monk, Bradley J.
Parkinson, Christine
Lim, Myong Cheol
O'Malley, David M.
Oaknin, Ana
Wilson, Michelle K.
Coleman, Robert L.
Lorusso, Domenica
Bessette, Paul
Ghamande, Sharad
Christopoulou, Athina
Provencher, Diane
Prendergast, Emily
Demirkiran, Fuat
Mikheeva, Olga
Yeku, Oladapo
Chudecka-Glaz, Anita
Schenker, Michael
Littell, Ramey D.
Safra, Tamar
Chou, Hung-Hsueh
Morgan, Mark A.
Drochytek, Vit
Barlin, Joyce N.
Van Gorp, Toon
Ueland, Fred
Lindahl, Gabriel
Anderson, Charles
Collins, Dearbhaile C.
Moore, Kathleen
Marme, Frederik
Westin, Shannon N.
McNeish, Iain A.
Shih, Danny
Lin, Kevin K.
Goble, Sandra
Hume, Stephanie
Fujiwara, Keiichi
Kristeleit, Rebecca S.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (34) : 3952 - 3964
[2] ATHENA-MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer
Monk, Bradley J.
Parkinson, Christine
Lim, Myong Cheol
O'Malley, David M.
Oaknin, Ana
Wilson, Michelle K.
Coleman, Robert L.
Lorusso, Domenica
Oza, Amit M.
Ghamande, Sharad A.
Christopoulou, Athina
Prendergast, Emily
Demirkiran, Fuat
Littell, Ramey D.
Chudecka-Glaz, Anita M.
Morgan, Mark Aloysuis
Goble, Sandra M.
Hume, Stephanie
Fujiwara, Keiichi
Kristeleit, Rebecca
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
[3] EFFICACY ANALYSIS BY DISEASE RISK SUBGROUP FOR THE PHASE 3 ATHENA-MONO STUDY (GOG3020/ENGOT-OV45) EVALUATING RUCAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH NEWLY DIAGNOSED OVARIAN CANCER
O'Malley, David
Christopoulou, Athina
Lim, Myong Cheol
Diaz, John
Demirkiran, Fuat
Wilson, Michelle
Jewell, Andrea
Drochytek, Vit
Bessette, Paul
Morris, Robert
Van Gorp, Toon
Van Le, Linda
Lindahl, Gabriel
Eskander, Ramez
Collins, Dearbhaile
Goble, Sandra
Hume, Stephanie
Fujiwara, Keiichi
Monk, Bradley
Kristeleit, Rebecca
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A16 - A16
[4] ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
Monk, Bradley J.
Coleman, Robert L.
Fujiwara, Keiichi
Wilson, Michelle K.
Oza, Amit M.
Oaknin, Ana
O'Malley, David M.
Lorusso, Domenica
Westin, Shannon N.
Safra, Tamar
Herzog, Thomas J.
Marme, Frederik
Eskander, Ramez
Lin, Kevin K.
Shih, Danny
Goble, Sandra
Grechko, Nikolay
Hume, Stephanie
Maloney, Lara
McNeish, Iain A.
Kristeleit, Rebecca S.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (12) : 1589 - 1594
[5] ATHENA (GOG-3020/ENGOT-ov45): a randomized, double-blind, placebo-controlled, Phase III study of rucaparib plus nivolumab following front-line platinum-based chemotherapy in ovarian cancer
Westin, Shannon N.
Kristeleit, Rebecca S.
Coleman, Robert L.
Fujiwara, Keiichi
Oza, Amit M.
O'Malley, David M.
Herzog, Thomas J.
Marme, Frederik
Oaknin, Ana
Eskander, Ramez
Lorusso, Domenica
Safra, Tamar
Korach, Jacob
Lin, Kevin K.
Shih, Danny
Caunt, Lisa
Goble, Sandra
Hume, Stephanie
Maloney, Lara
McNeish, Iain
Monk, Bradley J.
CANCER RESEARCH, 2019, 79 (13)
[6] ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled, phase 3 study of rucaparib plus nivolumab following front-line platinum-based chemotherapy in ovarian cancer
Goh, Jeffrey C.
Baron-Hay, Sally
Bonaventura, Tony
Buck, Martin
Dean, Andrew
Friedlander, Michael
Gao, Bo
Mileshkin, Linda
Oehler, Martin K.
Steer, Christopher
Vi Nguyen
Goble, Sandra
Grechko, Nikolay
Monk, Bradley J.
Kristeleit, Rebecca S.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 196 - 196
[7] ATHENA (GOG-3020/ENGOT-OV45): A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF RUCAPARIB plus NIVOLUMAB FOLLOWING FRONT-LINE PLATINUM-BASED CHEMOTHERAPY IN OVARIAN CANCER
Monk, B. J.
Coleman, R. L.
Fujiwara, K.
Oza, A. M.
Westin, S. N.
O'Malley, D. M.
Herzog, T. J.
Marme, F.
Oaknin, A.
Eskander, R.
Lorusso, D.
Korach, J.
Lin, K. K.
Shih, D.
Goble, S.
Grechko, N.
Hume, S.
Maloney, L.
McNeish, I.
Kristeleit, R. S.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 1019 - 1020
[8] ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib 1 the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Fujiwara, K.
Chou, H-H.
Kim, J-W.
Tan, D. S.
Tamura, K.
Katsumata, N.
Harano, K.
Hasegawa, K.
Hume, S.
Jones, E.
Goble, S.
Sullivan, L.
Shih, D.
Coleman, R. L.
McNeish, I.
Monk, B.
Kristeleit, R.
ANNALS OF ONCOLOGY, 2019, 30
[9] ATHENA (GOG-3020/ENGOT-OV45; EUDRACT 2017-004557-17; NCT03522246): A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF THE POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR RUCAPARIB + THE PD-1 INHIBITOR NIVOLUMAB FOLLOWING FRONTLINE PLATINUM-BASED CHEMOTHERAPY IN OVARIAN CANCER (OC)
Christopoulou, A.
Marme, F.
Oaknin, A.
Lorusso, D.
Safra, T.
Lindahl, G.
Chudecka-Glaz, A.
Ciuleanu, T.
Collins, D. C.
Demirkiran, F.
Lifrenko, I.
Van Gorp, T.
Coleman, R. L.
Fujiwara, K.
Oza, A. M.
Westin, S. N.
O'Malley, D. M.
Herzog, T. J.
Eskander, R.
Wilson, M.
Argire, S.
Grechko, N.
McNeish, I. A.
Monk, B. J.
Kristeleit, R. S.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A130 - A131
[10] Primary Results From IMagyn050/GOG 3015/ENGOT-OV39, a Double-Blind Placebo-Controlled Randomized Phase 3 Trial of Bevacizumab-Containing Therapy +/- Atezolizumab for Newly Diagnosed Stage III/IV Ovarian Cancer
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (11) : 12 - 13

← 1 2 3 4 5 →